Nanomateriales en la reparación del islote pancreático: transporte de células e implantes

Autores/as

  • Alicia Morocho
  • Cristóbal Espinoza
  • Alex Morales
  • Ronal Aldaz
  • María de los Ángeles Andrade
  • Liliana Chaglla

Palabras clave:

Diabetes mellitus, nanotecnología, trasplante pancreático, trasplante de islotes pancreáticos, control glicémico.

Resumen

La diabetes mellitus es una condición con un alto índice de morbimortalidad, que requiere de un manejo estricto para evitar la aparición de complicaciones. Sin embargo, las opciones terapéuticas disponibles apuntan al control glicémico como método preventivo, dejando de lado la opción curativa. No obstante, los avances en el ámbito de los trasplantes y la nanotecnología han abierto de nuevo la posibilidad de curar esta enfermedad. En efecto, en vista de las múltiples limitantes asociadas a opciones quirúrgicas como el trasplante de islotes pancreáticos, se ha propuesto la posibilidad de implementar nanotecnología como medio de transporte para minimizar el riesgo de rechazo y la necesidad de terapia inmunosupresora. El objetivo de esta revisión es evaluar cómo la nanotecnología ha ayudado a solventar los retos asociados al trasplante de islotes y su posible aplicabilidad a futuro en humanos.

Descargas

Los datos de descargas todavía no están disponibles.

Citas

Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohlrogge AW, et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018 Apr;138:271–81.

Forouzanfar MH, Afshin A, Alexander LT, Anderson HR, Bhutta ZA, Biryukov S, et al. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. The Lancet. 2016 Oct 8;388(10053):1659–724.

Yang JJ, Yu D, Wen W, Saito E, Rahman S, Shu XO, et al. Association of Diabetes with All-Cause and Cause-Specific Mortality in Asia: A Pooled Analysis of More Than 1 Million Participants. JAMA Netw Open. 2019 Apr 19;2(4):e192696.

Li X, Chattopadhyay K, Xu S, Chen Y, Xu M, Li L, et al. Prevalence of comorbidities and their associated factors in patients with type 2 diabetes at a tertiary care department in Ningbo, China: a cross-sectional study. BMJ Open. 2021 Jan 7;11(1):e040532.

American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021. Diabetes Care. 2020 Dec 4;44(Supplement_1):S111–24.

Fellner C. Novel Treatments Target Type-2 Diabetes. Pharm Ther. 2016 Oct;41(10):650–3.

Farney AC, Sutherland DER, Opara EC. Evolution of Islet Transplantation for the Last 30 Years. Pancreas. 2016 Jan;45(1):8–20.

Shapiro AMJ, Pokrywczynska M, Ricordi C. Clinical pancreatic islet transplantation. Nat Rev Endocrinol. 2017 May;13(5):268–77.

Ernst AU, Bowers DT, Wang LH, Shariati K, Plesser MD, Brown NK, et al. Nanotechnology in cell replacement therapies for type 1 diabetes. Adv Drug Deliv Rev. 2019 Jan 15;139:116–38.

Kelly WD, Lillehei RC, Merkel FK, Idezuki Y, Goetz FC. Allotransplantation of the pancreas and duodenum along with the kidney in diabetic nephropathy. Surgery. 1967 Jun;61(6):827–37.

Kandaswamy R, Stock PG, Miller J, White J, Booker SE, Israni AK, et al. OPTN/SRTR 2020 Annual Data Report: Pancreas. Am J Transplant. 2022;22(S2):137–203.

Meirelles RF, Salvalaggio P, Pacheco-Silva A. Pancreas transplantation: review. Einstein. 2015;13(2):305–9.

Farney AC, Rogers J, Stratta RJ. Pancreas graft thrombosis: causes, prevention, diagnosis, and intervention. Curr Opin Organ Transplant. 2012 Feb;17(1):87–92.

Amorese G, Lombardo C, Tudisco A, Iacopi S, Menonna F, Marchetti P, et al. Induction and Immunosuppressive Management of Pancreas Transplant Recipients. Curr Pharm Des. 2020;26(28):3425–39.

Wiseman AC, Wainright JL, Sleeman E, McBride MA, Baker T, Samana C, et al. An analysis of the lack of donor pancreas utilization from younger adult organ donors. Transplantation. 2010 Sep 15;90(5):475–80.

London NJ, Donnelly PK. Techniques of pancreas and islet transplantation. Baillieres Clin Gastroenterol. 1994 Sep;8(3):517–32.

Maupoey Ibáñez J, Boscà Robledo A, López-Andujar R. Late complications of pancreas transplant. World J Transplant. 2020 Dec 28;10(12):404–14.

Van Belle T, von Herrath M. Immunosuppression in islet transplantation. J Clin Invest. 2008 May 1;118(5):1625–8.

Shapiro AM, Lakey JR, Ryan EA, Korbutt GS, Toth E, Warnock GL, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med. 2000 Jul 27;343(4):230–8.

Drachenberg CB, Klassen DK, Weir MR, Wiland A, Fink JC, Bartlett ST, et al. Islet cell damage associated with tacrolimus and cyclosporine: morphological features in pancreas allograft biopsies and clinical correlation. Transplantation. 1999 Aug 15;68(3):396–402.

Hwang JL, Weiss RE. Steroid-induced diabetes: a clinical and molecular approach to understanding and treatment. Diabetes Metab Res Rev. 2014 Feb;30(2):96–102.

Vaithilingam V, Bal S, Tuch BE. Encapsulated Islet Transplantation: Where Do We Stand? Rev Diabet Stud RDS. 2017;14(1):51–78.

van Suylichem PT, Strubbe JH, Houwing H, Wolters GH, van Schilfgaarde R. Insulin secretion by rat islet isografts of a defined endocrine volume after transplantation to three different sites. Diabetologia. 1992 Oct;35(10):917–23.

Severino P, da Silva CF, Andrade LN, de Lima Oliveira D, Campos J, Souto EB. Alginate Nanoparticles for Drug Delivery and Targeting. Curr Pharm Des. 2019;25(11):1312–34.

de Vos P, Faas MM, Strand B, Calafiore R. Alginate-based microcapsules for immunoisolation of pancreatic islets. Biomaterials. 2006 Nov;27(32):5603–17.

Ma Y, Zhang Y, Liu Y, Chen L, Li S, Zhao W, et al. Investigation of alginate-ε-poly-L-lysine microcapsules for cell microencapsulation. J Biomed Mater Res A. 2013 May;101(5):1265–73.

Lim F, Sun AM. Microencapsulated islets as bioartificial endocrine pancreas. Science. 1980 Nov 21;210(4472):908–10.

Robitaille R, Dusseault J, Henley N, Desbiens K, Labrecque N, Hallé JP. Inflammatory response to peritoneal implantation of alginate-poly-L-lysine microcapsules. Biomaterials. 2005 Jul;26(19):4119–27.

van Raamsdonk JM, Cornelius RM, Brash JL, Chang PL. Deterioration of polyamino acid-coated alginate microcapsules in vivo. J Biomater Sci Polym Ed. 2002;13(8):863–84.

Calafiore R, Basta G, Luca G, Lemmi A, Montanucci MP, Calabrese G, et al. Microencapsulated pancreatic islet allografts into nonimmunosuppressed patients with type 1 diabetes: first two cases. Diabetes Care. 2006 Jan;29(1):137–8.

Soon-Shiong P, Heintz RE, Merideth N, Yao QX, Yao Z, Zheng T, et al. Insulin independence in a type 1 diabetic patient after encapsulated islet transplantation. Lancet Lond Engl. 1994 Apr 16;343(8903):950–1.

Tuch BE, Keogh GW, Williams LJ, Wu W, Foster JL, Vaithilingam V, et al. Safety and Viability of Microencapsulated Human Islets Transplanted Into Diabetic Humans. Diabetes Care. 2009 Oct;32(10):1887–9.

Jacobs-Tulleneers-Thevissen D, Chintinne M, Ling Z, Gillard P, Schoonjans L, Delvaux G, et al. Sustained function of alginate-encapsulated human islet cell implants in the peritoneal cavity of mice leading to a pilot study in a type 1 diabetic patient. Diabetologia. 2013 Jul;56(7):1605–14.

Matsumoto S, Tan P, Baker J, Durbin K, Tomiya M, Azuma K, et al. Clinical porcine islet xenotransplantation under comprehensive regulation. Transplant Proc. 2014 Aug;46(6):1992–5.

Descargas

Publicado

2023-05-14